Valeritas’ V-Go nabs preferred status on OptumRx formularies

Valeritas (NSDQ:VLRX) said today that its wearable insulin delivery device, V-Go, won preferred status on the OptumRx formulary.

The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. The V-Go product is worn like a patch and delivers a preset basal rate of insulin over the course of 24 hours. The device can also deliver on-demand bolus dosing at mealtimes.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas’ V-Go nabs preferred status on OptumRx formularies appeared first on MassDevice.

from MassDevice http://bit.ly/2SOEZbP